



DLA Piper US LLP
153 Townsend Street, Suite 800
San Francisco, California 94107-1957
www.dlapiper.com

Linda R. Judge
linda.judge@dlapiper.com
T 415.836.2586

RECEIVED
CENTRAL FAX CENTER

NOV 21 2006

FAX TRANSMISSION COVER SHEET

Date: November 21, 2006

To	Telephone	Fax Number
Attn: Group Art Unit 1644 United States Patent and Trademark Office		571.273.8300

From:	Linda R. Judge 415/836.2586	Client-Matter Number:	306229-114
-------	--------------------------------	-----------------------	------------

Re:	U.S. Application No.:	10/807,449
	Entitled:	CYTOKINE-EXPRESSING CELLULAR VACCINE COMBINATIONS
	Filing Date:	March 24, 2004
	Inventor:	Jooss, et al.
	Art Unit:	1644
	Examiner:	Ouspenski, I.I.
	Attorney Docket No.:	3802-090-27 CIP

Pages:	-11- (Including this form)	Originals:	will not follow
--------	----------------------------	------------	-----------------

If there is a problem with this transmission, please call DLA Piper Office Services at 415.836.2500, ext. 6104

Fax Operator/Ext. _____

Message:

Please find the following papers included in this filing:

1. Transmittal; and
2. Amendment and Response to Restriction Requirement.

Thank you.

CONFIDENTIALITY NOTICE


This communication is ONLY for the person named above. Unless otherwise indicated, it contains information that is confidential, privileged or exempt from disclosure under applicable law. If you are not the person named above, or responsible for delivering it to that person, be aware that disclosure, copying, distribution or use of this communication is strictly PROHIBITED. If you have received it in error, or are uncertain as to its proper handling, please immediately notify us by collect telephone and mail the original to us at the above address. Thank you.


(Form Rev. 8/02/04)

SANF1\359483.1

<h1>TRANSMITTAL FORM</h1> <p><i>(To be used for all correspondence after initial filing)</i></p>	Application No.	10/807,449	RECEIVED CENTRAL FAX CENTER NOV 21 2006
	Filing Date	March 24, 2004	
	First Named Inventor	Jooss, et al.	
	Group Art Unit	1644	
	Examiner Name	Ouspenski, I.I.	
Total Number of Pages in this Submission: 10		Attorney Docket No.	3802-090-27 CIP (306229-114)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> Response to Restriction <input type="checkbox"/> Affidavit/Declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement (IDS) <input type="checkbox"/> Substitute PTO Form 1449 <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts Notice/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Combined Revocation and Power of Attorney and 37 C.F.R. §3.73(b) and 3.71 Statements and Request for Change of Attorney Docket Number <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD. Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After-Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (<i>Appeal Notice, Brief, Reply Brief</i>) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Additional Enclosure(s): <input type="checkbox"/> Return Receipt Postcard
Remarks: Please address all correspondence to Customer Number 29585 The Director is hereby authorized to charge any fees that may be required in connection with the papers submitted herewith that have been inadvertently omitted, specifically including any extension fees that may be required under 37 CFR § 1.138(a), to Deposit Account No. 07-1896 (Charge No. 3802-090-27 CIP (306229-114))		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT				
Signature		Date	November 21, 2006	
Name	Linda R. Judge	Reg. No.	42,702	
Address	153 Townsend Street, 8th Floor, San Francisco, CA 94107		Telephone	415/836.2586
			Facsimile	415/836.2501

CERTIFICATE OF FACSIMILE TRANSMISSION	
I hereby certify that this paper (along with any referred to as being attached or enclosed) is being filed with the United States Patent and Trademark Office by facsimile transmission on the date indicated below to Facsimile No. 571/273.8300.	
Date:	November 21, 2006
	 Print Name

SANFI359482.1

RECEIVED
CENTRAL FAX CENTER

NOV 21 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jooss, et al.

Docket No: 3802-090-27 CIP
(306229-114)

Serial No.: 10/807,449

Confirmation No.: 3354

Filed: March 24, 2004

Group Art Unit: 1644

For: CYTOKINE-EXPRESSING CELLULAR
VACCINE COMBINATIONS

Examiner: Oupenski, I.I.

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

VIA FACSIMILE to 571/273.8300

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Responsive to the Restriction/Election of Species Requirement in the above-captioned application, dated October 24, 2006, Applicants elect, Groups I – XX (Claims 1-10, 12, 14, 15, 19, 20 and 23-27), and in particular an anti-OX40 antibody, with traverse, for further prosecution at this time.

Amendments of the Claims begin at page 2 of this paper.**Remarks** begin on page 8 of this paper.